Clinical Trial Update: ADI-PEG in Patients With Metastatic Melanoma [Phase 1]

View source ↗

Summary

Phase 1 study of ADI-PEG 20 in patients with metastatic melanoma has completed, yielding preliminary safety and tolerability data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ADI-PEG 20 (pegylated arginine deiminase)

Snippet

Sponsor: FDA Office of Orphan Products Development | Conditions: Melanoma, Neoplasm Metastasis | Phase 1 | Status: COMPLETED